Hostname: page-component-669899f699-swprf Total loading time: 0 Render date: 2025-04-28T05:58:37.828Z Has data issue: false hasContentIssue false
  • English
  • Français

Venlafaxine Treatment of Trichotillomania: An Open Series of Ten Cases

Published online by Cambridge University Press:  07 November 2014

Richard L. O'Sullivan ,
Nancy J. Keuthen ,
Dayami Rodriguez ,
Paige Goodchild ,
Gary A. Christenson ,
Scott L. Rauch ,
Michael A. Jenike  and
Lee Baer
Get access Rights & Permissions [Opens in a new window]

Abstract

In this article, we discuss the use of venlafaxine, an antidepressant with predominant effects at both noradrenergic and serotonergic reuptake sites, in the treatment of trichotillomania (TTM), a complex psychiatric condition manifested by chronic, severe hair pulling. We review case examples of 10 consecutive patients exhibiting moderately severe TTM symptoms, as judged by self-report, extent of hair loss, and duration of remission, and discuss our observations regarding the effects of venlafaxine therapy (mean dose, 274 mg/day) on these patients over the course of several months (mean, 15.1 weeks). The Massachusetts General Hospital Hair Pulling Scale, Massachusetts General Hospital Trichotillomania Impact Scale (MGH TIS), Psychiatric Institute Trichotillomania Scale (PITS), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and Clinical Global Improvement (CGI) scale were used to appraise the patients' condition during routine clinical visits. A retrospective chart review of clinical data demonstrated significant improvement in TTM symptoms from baseline to last clinical visit in both behavioral (MGH HPS, P=.02; PITS, P=.02) and psychosocial (MGH TIS, P=.009) terms. Mean improvement on the CGI scale was 2.38±1.51, between “much improved” (2) and “slightly improved” (3). There were no significant differences from baseline to endpoint scores on the BDI or BAI. This retrospective treatment review indicates that short-term treatment with venlafaxine improved TTM symptoms; however, longer controlled trials with extended baseline periods are needed for optimal assessment of pharmacologic treatment of TTM. We look to future studies to confirm and supplement our initial positive findings.

Type
Feature Article
Information
CNS Spectrums , Volume 3 , Issue 9: Trichotillomania: A New Understanding , October 1998 , pp. 56 - 63
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

REFERENCES

1.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
2.Christenson, GA, Mackenzie, TB, Mitchell, JE. Characteristics of 60 adult chronic hair pullers. Am J Psychiatry. 1991;148:365–370.Google Scholar
3.Soriano, J, O'Sullivan, RL, Baer, L, Phillips, K, McNally, RJ, Jenike, MA. Trichotillomania and self-esteem: a survey of sixty-two female hairpullers. J Clin Psychiatry. 1996;57:77–82.Google Scholar
4.O'Sullivan, RL, Keuthen, N, Gumley, G, Jenike, MA. Carpal tunnel syndrome and trichotillomania. J Clin Psychiatry. 1996;57:17.Google ScholarPubMed
5.Minichiello, WE, O'Sullivan, RL, Osgood-Hynes, D, Baer, L. Trichotillomania: clinical aspects and treatment strategies. Harvard Rev Psychiatry. 1994;1:336–44.Google Scholar
6.Christenson, GA, Pyle, RL, Mitchell, JE. Estimated lifetime prevalence of trichotillomania in college students. J Clin Psychiatry. 1991;52:415–417.Google ScholarPubMed
7.King, RA, Zohar, AH, Ratzoni, G, et al.An epidemiological study of trichotillomania in Israeli adolescents. J Am Acad Child Adolesc Psychiatry. 1995;34:1212–1225.CrossRefGoogle ScholarPubMed
8.Christenson, GA, O'Sullivan, RL. Trichotillomania: rational treatment options. CNS Drugs. 1996;6:23–34.CrossRefGoogle Scholar
9.Christenson, GA, Crow, SJ. The characterization and treatment of trichotillomania. J Clin Psychiatry. In press.Google Scholar
10.Keuthen, NJ, O'Sullivan, RL, Jefferys, D. Trichotillomania: clinical concepts and treatment approaches. In: Jenike, MA, Baer, L, Minichiello, WE, eds. Obsessive-Compulsive Disorders: Theory and Management. 3rd ed. Philadelphia, Pa: Mosby Year Book; 1998.Google Scholar
11.Swedo, SE, Leonard, HL, Rapoport, JL, Lenane, MC, Goldberger, EL, Cheslow, DL. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania. N Engl J Med. 1989;321:497–501.Google Scholar
12.Pigott, TA, L'Heueux, F, Grady, TA, et al. Controlled comparison of clomipramine and fluoxetine in trichotillomania. In: Abstracts of Panels and Posters of the 31st Annual Meeting of the American College of Neuropsychopharmacology. 1992; San Juan, Puerto Rico.Google Scholar
13.Christenson, GA, Mackenzie, TB, Mitchell, JE, Callies, AL. A placebo-controlled double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry. 1991;148:1566–1571.Google Scholar
14.Streichenwein, SM, Thornby, JI. A long-term, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry. 1995;152:1192–1196.Google ScholarPubMed
15.Koran, LM, Ringold, A, Hewlett, W. Fluoxetine for trichotillomania: an open clinical trial. Psychopharmacol Bull. 1992;28:145–149.Google Scholar
16.Winchel, RM, Jones, JS, Stanley, B, Molcho, A, Stanley, M. Clinical characteristics of trichotillomania and its response to fluoxetine. J Clin Psychiatry. 1992;53:304–308.Google Scholar
17.Stanley, MA, Bowers, TC, Swann, AC, Taylor, DJ. Treatment of trichotillomania with fluoxetine. J Clin Psychiatry. 1991;52:282.Google Scholar
18.Stein, DJ, Bouwer, C, Maud, CM. Use of the selective serotonin reuptake inhibitor eitalopram in treatment of trichotillomania. Eur Arch Psychiatry Clin Neurosci. 1997;234–236.Google Scholar
19.Christenson, GA, Popkin, MK, Mackenzie, TB, Realmuto, CM. Lithium treatment of chronic hair pulling. J Clin Psychiatry. 1991;52:116–120.Google Scholar
20.Snyder, S. Trichotillomania treated with amitriptyline. J Nerv Ment Dis. 1980;168:505–507.CrossRefGoogle ScholarPubMed
21.Sachdeva, JS, Sidhu, BS. Trichotillomania associated with depression. J Indian Med Assoc. 1987;85:151–152.Google Scholar
22.Stein, DJ, Hollander, E. Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry. 1992;53:123–126.Google Scholar
23.VanAmerigen, M, Mancini, C. Treatment of trichotillomania with haloperidol. Presented at Anxiety Disorders Association of America Annual Meeting; 1996. Orlando Fla.Google Scholar
24.Christenson, GA, Crow, SJ, Mackenzie, TB, Crosby, RD, Mitchell, JE. A placebo controlled double-blind study of naltrexone for trichotillomania. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 26, 1994; Philadelphia, Pa. Abstract NR 597:212.Google Scholar
25.Swedo, SE, Lenane, MC, Leonard, HL. Long-term treatment of trichotillomania (hair pulling). N Engl J Med. 1993;329:141–142.CrossRefGoogle ScholarPubMed
26.Winchel, RM, Jones, JS, Molcho, A, Parsons, B, Stanley, B, Stanley, M. The Psychiatric Institute Trichotillomania Scale (PITS). Psychopharmacol Bull. 1992;28:463–476.Google ScholarPubMed
27.Keuthen, N, O'Sullivan, RL, Ricciardi, J, et al.The MGH Hairpulling Scale. I. Scale development and factor analyses. Psychother Psychosom. 1995;64:141–145.Google Scholar
28.O'Sullivan, RL, Keuthen, N, Hayday, CF, et al.The MGH Hairpulling Scale: II. reliability and validity. Psychother Psychosom. 1995;64:146–148.Google Scholar
29.Montgomery, SA. Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry. 1993;54:119–126.Google Scholar
30.Geracioli, TD. Venlafaxine treatment of panic disorders: a case series. J Clin Psychiatry. 1995;56:408–410.Google Scholar
31.Emmanuel, NP, et al. Venlafaxine in social phobia: a case series. Presented at the American Psychiatric Association Annual Meeting; May 21–25, 1995; Miami Beach, Fla.Google Scholar
32.Zajecka, JM, Fawcett, J, Guy, C. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine. J Clin Psychopharmacol. 1990;10:151–152.Google Scholar
33.Yaryura-Tobias, JA, Neziroglu, FA, McKay, DR. The action of venlafaxine on obsessive-compulsive disorder, (abstract). Biol Psychiatry. 1994;35:737.Google Scholar
34.Ananth, J, Burgoyne, K, Smith, M, Swartz, R. Venlafaxine treatment of obsessive-compulsive disorder. Am J Psychiatry; 1995,152:1832.Google ScholarPubMed
35.Grossman, R, Hollander, E. Treatment of obsessive-compulsive disorder with venlafaxine. Am J Psychiatry. 1996;153:576–577.Google Scholar
36.Rauch, SL, O'Sullivan, RL, Jenike, MA. Open treatment of OCD with venlafaxine: a series of ten cases. J Clin Psychopharmacol. 1996;16:81–83.Google Scholar
37.Beck, AT, Ward, CH, Mendelsohn, M, Mock, J, Erbaugh, J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571.Google Scholar
38.Beck, AT, Epstein, N, Brown, G, Steer, R. An inventory for measuring anxiety: psychometric properties. J Clin Psychol. 1988;893–897.Google Scholar
39.Guy, W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Department of Health, Education, and Welfare. Publication No. (ADM); 1976.Google Scholar
40.Ninan, PT, Knight, B, Johns, B, Kirk, L, Logan, C, Rothbaum, B. Trichotillomania: a controlled trial of venlafaxine. Poster No. 55. Presented at New Clinical Drug Evaluation Unit Program; 1997.Google Scholar
41.Keuthen, NJ, O'Sullivan, RL, Goodchild, G, Rodriguez, D, Jenike, MA, Baer, L. A retrospective review of treatment outcome in 63 hairpullers. Am J Psychiatry. In press.Google Scholar
42.Cohen, LJ, Stein, DJ, Simeon, D, et al.Clinical profile, comorbidity, and treatment history in 123 hair pullers: a survey study. J Clin Psychiatry. 7:319–326.Google Scholar